Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Location: United States, New Jersey, Plainsboro Township
Employees: 51-200
Phone: +1 609-452-9813
Founded date: 2002
Investors 1
| Date | Name | Website |
| - | Centrecour... | centrecour... |
Mentions in press and media 5
| Date | Title | Description |
| 08.06.2018 | Rubius snaps up Novartis vet Pablo Cagnoni as CEO; MiMedx dumps two execs following internal investigation | → David Epstein has recruited another fellow Novartis vet to Rubius Therapeutics, the cell therapy startup that he’s chairing — this time straight to the top job. New CEO Pablo Cagnoni joins Flagship Pioneering partner ... |
| 11.08.2016 | Protocols: Infinity hunts up a buyer for its disappointing cancer drug duvelisib; Is Northwest Bio finally broke? | AbbVie’s decision to abruptly pull out of its partnership with Infinity on duvelisib largely wrecked the company’s hopes to finally make it big after repeated setbacks over the years. But Infinity CEO Adelene Perkin... |
| 22.07.2014 | MedImmune and Advaxis partner on immuno-oncology combination clinical trial | MedImmune and Advaxis partner on immuno-oncology combination clinical trial 22-07-2014 AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advax... |
| 01.11.2012 | Immunotherapy developer secures $11.4 million for cervical cancer treatment | Solution/product: It is developing treatments for advanced cervical cancer and head and neck cancers caused by the human papillomavirus. The immunotherapy treatment targets cells expressing the HPV gene E7 that change infected cells into ma... |
| - | Immunotherapy developer secures $11.4 million for cervical cancer treatment | Company name: Advaxis. Industry: biopharmaceuticals. Location: Princeton, New Jersey. Solution/product: It is developing treatments for advanced cervical cancer and head and neck cancers caused by the human papillomavirus. The immunotherapy... |